programmed death receptor ligand 1
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
... The interaction between PD-L1 and the PD-1 receptor on T cells leads to an inhibitory signal that constrains the function of activated lymphocytes [33]. Thus, PD-L1 overexpression is postulated to be a ...
12
Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives
... PD‑1: programmed cell death 1; PD‑L1: programmed cell death 1 ligand 1; CTLA4: cytotoxic T‑lymphocyte‑associated antigen‑4; DC: dendritic cell; TME: tumor ...
11
A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction
... and there are no T cells in these cultures providing PD-1. While the PD-1:PD-L1 pathway is well established in adaptive immunity during chronic infections and cancer, its role in acute infections is less ...
11
CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma
... CXC receptor 2; CXCL1: CXC ligand 1; RFS: Recurrence-free survival; OS: Overall survival; PD-L1: Programmed cell death 1 ligand 1; Treg: Regulatory T; MMP9: Matrix ...
10
Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes
... CD86, programmed death (PD-1), programmed death ligand 1 (PD-L1), paired immunoglobulin-like receptor B (PIR-B) or T-cell proliferation in serum, spleen homogenate, ...
10
Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients
... the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway by anti-PD-L1 antibody decreased apoptosis of human peripheral T cells from septic patients ...
9
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study
... factor receptor (EGFR), vascular endo- thelial growth factor (VEGF), mammalian target of rapa- mycin (mTOR), insulin-like growth factor 1 receptor (IGF-1R), or fibroblast growth factor ...
8
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma
... Programmed death 1 (PD-1) receptor is an inhibi- tory T cell receptor expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 of the B7-ligand superfamily ...
5
CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment
... PD-1: Programmed cell death receptor-1; PD-L1: Programmed cell death ligand-1; NSCLC: Non- small-cell lung cancer; ADC: Adenocarcinoma; SCC: Squamous cell ...
15
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
... anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of non-small cell lung cancer (NSCLC), but ...
6
<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>
... Use of atzolizumab was approved by the FDA as a second-line therapy based on the fi ndings from a phase II clinical trial, and was veri fi ed in the OAK III clinical trial. Compared with docetaxel, atzolizumab showed ...
17
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
... T-cell receptor sequencing (TCRseq) ...file 1: Table S1Table ...file 1: Table S1Table S6); one of these clones was detected in the original primary tumor ...file 1: Table S1Table S6) per- ...
8
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
... the programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) axis ...identified ligand of PD-1 [15, ...
11
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
... T790M and EGFR-TKIs plus c-met inhibitors for c-met amplification [32]. However, the role of immunotherapy in EGFR-TKIs-resistant patients has not been revealed. Chen N et al. [23] demonstrated that the protein level of ...
11
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
... cell receptor deep sequencing provides the full spectrum of the B and T cell receptor repertoire and can be used to potentially identify immunosequencing biomarkers in both peripheral blood and tumor ...
25
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
... immune checkpoint inhibition seem to compare favor- ably to those of other tumor types [47]. With the recent FDA approval of avelumab for previously-treated ad- vanced MCC, patients with MCC now have a new treat- ment ...
6
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
... Background: Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such ...
5
Wnt/beta-catenin pathway: modulating anticancer immune response
... Nusse and Varmus discovered the components of the Wnt/β-catenin pathway in 1982 while studying onco- genic mechanisms of mouse mammary tumor virus (MMTV) [1]. Proviral insertion at the “integration site” was ...
12
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
... ing, 1 for weak staining, 2 for moderate staining, and 3 for strong ...scored 1, 26%–50% scored 2, 51%–75% scored 3, and 76%–100% scored 4 ...− 1) were used to determine the optimal cut-off score of ...
14
Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
... Immune-checkpoint inhibitors targeting PD-1 and PD-L1 have shown promising clinical results for GC [36–38]. The recent advances in the relationship between gene expression and TME in gastric cancer patients [39– ...
13